Courtney Cook
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Courtney Cook has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
16 shared publications - Ryan Ottwell
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
7 shared publications - Alexis Wirtz
Oklahoma State University Center for Health Sciences Tulsa, OK United States
5 shared publications - Micah Hartwell
Department of Psychiatry and Behavioral Sciences , Oklahoma State University Center for Health Sciences , Tulsa , OK , USA
5 shared publications - Alyson Haslam
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
4 shared publications - Andriana M. Peña
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
4 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1: Flow diagram for study inclusion.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1: Flow diagram for study inclusion.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1701-1711
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1701-1711
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- Open Access
- 24 February 2022
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 5 (1) , e33996
Spin in Abstracts of Systematic Reviews and Meta-analyses of Melanoma Therapies: Cross-sectional Analysis
Background: Spin is defined as the misrepresentation of a study’s results, which may lead to misperceptions or misinterpretation of the findings. Spin has previously been found in randomized controlled trials and systematic reviews of acne vulgaris treatments and treatments of various nondermatological conditions. Objective: The purpose of this study was to quantify the presence of spin in abstracts of systematic reviews and meta-analyses of melanoma therapies and identify any related secondary characteristics of these articles. Methods: We used a cross-sectional approach on June 2, 2020, to search the MEDLINE and Embase databases from their inception. To meet inclusion criteria, a study was required to be a systematic review or meta-analysis pertaining to the treatment of melanoma in human subjects, and reported in English. We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) definition of systematic reviews and meta-analyses. Data were extracted in a masked, duplicate fashion. We conducted a powered bivariate linear regression and calculated odds ratios for each study characteristic. Results: A total of 200 systematic reviews met the inclusion criteria. We identified spin in 38% (n=76) of the abstracts. The most common type of spin found was type 3 (selective reporting of or overemphasis on efficacy outcomes or analysis favoring the beneficial effect of the experimental intervention), occurring 40 times; the least common was type 2 (title claims or suggests a beneficial effect of the experimental intervention not supported by the findings), which was not present in any included abstracts. We found that abstracts pertaining to pharmacologic interventions were 3.84 times more likely to contain spin. The likelihood of an article containing spin has decreased annually (adjusted odds ratio 0.91, 95% CI 0.84-0.99). No significant correlation between funding source or other study characteristics and the presence of spin was identified. Conclusions: We have found that spin is fairly common in the abstracts of systematic reviews of melanoma treatments, but the prevalence of spin in these abstracts has been declining from 1992-2020.
- 24 February 2022
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 5 (1) , e33996
Open AccessSpin in Abstracts of Systematic Reviews and Meta-analyses of Melanoma Therapies: Cross-sectional Analysis
Background: Spin is defined as the misrepresentation of a study’s results, which may lead to misperceptions or misinterpretation of the findings. Spin has previously been found in randomized controlled trials and systematic reviews of acne vulgaris treatments and treatments of various nondermatological conditions. Objective: The purpose of this study was to quantify the presence of spin in abstracts of systematic reviews and meta-analyses of melanoma therapies and identify any related secondary characteristics of these articles. Methods: We used a cross-sectional approach on June 2, 2020, to search the MEDLINE and Embase databases from their inception. To meet inclusion criteria, a study was required to be a systematic review or meta-analysis pertaining to the treatment of melanoma in human subjects, and reported in English. We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) definition of systematic reviews and meta-analyses. Data were extracted in a masked, duplicate fashion. We conducted a powered bivariate linear regression and calculated odds ratios for each study characteristic. Results: A total of 200 systematic reviews met the inclusion criteria. We identified spin in 38% (n=76) of the abstracts. The most common type of spin found was type 3 (selective reporting of or overemphasis on efficacy outcomes or analysis favoring the beneficial effect of the experimental intervention), occurring 40 times; the least common was type 2 (title claims or suggests a beneficial effect of the experimental intervention not supported by the findings), which was not present in any included abstracts. We found that abstracts pertaining to pharmacologic interventions were 3.84 times more likely to contain spin. The likelihood of an article containing spin has decreased annually (adjusted odds ratio 0.91, 95% CI 0.84-0.99). No significant correlation between funding source or other study characteristics and the presence of spin was identified. Conclusions: We have found that spin is fairly common in the abstracts of systematic reviews of melanoma treatments, but the prevalence of spin in these abstracts has been declining from 1992-2020.
- Open Access
- 5 October 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Spin in Abstracts of Systematic Reviews and Meta-Analyses of Melanoma Therapies: A Cross-Sectional Analysis
BACKGROUND Spin is defined as the misrepresentation of a study’s results, which may lead to misperceptions or misinterpretation of the findings. Spin has previously been found in randomized controlled trials and systematic reviews of acne vulgaris treatments and treatments of various nondermatological conditions. OBJECTIVE The purpose of this study was to quantify the presence of spin in abstracts of systematic reviews and meta-analyses of melanoma therapies and identify any related secondary characteristics of these articles. METHODS We used a cross-sectional approach on June 2, 2020, to search the MEDLINE and Embase databases from their inception. To meet inclusion criteria, a study was required to be a systematic review or meta-analysis pertaining to the treatment of melanoma in human subjects, and reported in English. We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) definition of systematic reviews and meta-analyses. Data were extracted in a masked, duplicate fashion. We conducted a powered bivariate linear regression and calculated odds ratios for each study characteristic. RESULTS A total of 200 systematic reviews met the inclusion criteria. We identified spin in 38% (n=76) of the abstracts. The most common type of spin found was type 3 (selective reporting of or overemphasis on efficacy outcomes or analysis favoring the beneficial effect of the experimental intervention), occurring 40 times; the least common was type 2 (title claims or suggests a beneficial effect of the experimental intervention not supported by the findings), which was not present in any included abstracts. We found that abstracts pertaining to pharmacologic interventions were 3.84 times more likely to contain spin. The likelihood of an article containing spin has decreased annually (adjusted odds ratio 0.91, 95% CI 0.84-0.99). No significant correlation between funding source or other study characteristics and the presence of spin was identified. CONCLUSIONS We have found that spin is fairly common in the abstracts of systematic reviews of melanoma treatments, but the prevalence of spin in these abstracts has been declining from 1992-2020.
- 5 October 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSpin in Abstracts of Systematic Reviews and Meta-Analyses of Melanoma Therapies: A Cross-Sectional Analysis
BACKGROUND Spin is defined as the misrepresentation of a study’s results, which may lead to misperceptions or misinterpretation of the findings. Spin has previously been found in randomized controlled trials and systematic reviews of acne vulgaris treatments and treatments of various nondermatological conditions. OBJECTIVE The purpose of this study was to quantify the presence of spin in abstracts of systematic reviews and meta-analyses of melanoma therapies and identify any related secondary characteristics of these articles. METHODS We used a cross-sectional approach on June 2, 2020, to search the MEDLINE and Embase databases from their inception. To meet inclusion criteria, a study was required to be a systematic review or meta-analysis pertaining to the treatment of melanoma in human subjects, and reported in English. We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) definition of systematic reviews and meta-analyses. Data were extracted in a masked, duplicate fashion. We conducted a powered bivariate linear regression and calculated odds ratios for each study characteristic. RESULTS A total of 200 systematic reviews met the inclusion criteria. We identified spin in 38% (n=76) of the abstracts. The most common type of spin found was type 3 (selective reporting of or overemphasis on efficacy outcomes or analysis favoring the beneficial effect of the experimental intervention), occurring 40 times; the least common was type 2 (title claims or suggests a beneficial effect of the experimental intervention not supported by the findings), which was not present in any included abstracts. We found that abstracts pertaining to pharmacologic interventions were 3.84 times more likely to contain spin. The likelihood of an article containing spin has decreased annually (adjusted odds ratio 0.91, 95% CI 0.84-0.99). No significant correlation between funding source or other study characteristics and the presence of spin was identified. CONCLUSIONS We have found that spin is fairly common in the abstracts of systematic reviews of melanoma treatments, but the prevalence of spin in these abstracts has been declining from 1992-2020.
- Open Access
- 16 July 2021
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 4 (2) , e31902
Correction: The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis
[This corrects the article DOI: 10.2196/28415.].
- 16 July 2021
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 4 (2) , e31902
Open AccessCorrection: The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis
[This corrects the article DOI: 10.2196/28415.].
- Open Access
- 8 July 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Correction: The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 8 July 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCorrection: The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- Open Access
- 11 June 2021
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 4 (1) , e28415
The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis
Background: Person-centered language places a person’s identity before any disability or medical condition they may have. Using person-centered language reduces stigma and improves the patient-physician relationship, potentially optimizing health outcomes. Patients with psoriasis often feel stigmatized due to their chronic skin condition. Objective: We seek to evaluate the use of person-centered language in psoriasis literature and to explore whether certain article characteristics were associated with non–person-centered language. Methods: We performed a systematic search on PubMed for recently published articles in journals that regularly publish psoriasis studies. After article reduction procedures, randomization, and screening, we reached our target sample of 400 articles. The following non–person-centered language terms were extracted from each article: “Psoriasis Patient,” “Psoriasis subject,” “Affected with,” “Sufferer,” “Suffering from,” “Burdened with,” “Afflicted with,” and “Problems with.” Screening and data extraction occurred in a masked duplicate fashion. Results: Of the 400 included articles, 272 (68%) were not adherent to person-centered language guidelines according to the American Medical Association Manual of Style. The most frequent non–person-centered language term was “Psoriasis Patient,” found in 174 (43.5%) articles. The stigmatizing language was associated with the type of article and funding status, with original investigations and funded studies having higher rates of stigmatizing language. Conclusions: Articles about psoriasis commonly use non–person-centered language terms. It is important to shift away from using stigmatizing language about patients with psoriasis to avoid potential untoward influences. We recommend using “patients with psoriasis” or “patient living with psoriasis” to emphasize the importance of person-centered care.
- 11 June 2021
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 4 (1) , e28415
Open AccessThe Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis
Background: Person-centered language places a person’s identity before any disability or medical condition they may have. Using person-centered language reduces stigma and improves the patient-physician relationship, potentially optimizing health outcomes. Patients with psoriasis often feel stigmatized due to their chronic skin condition. Objective: We seek to evaluate the use of person-centered language in psoriasis literature and to explore whether certain article characteristics were associated with non–person-centered language. Methods: We performed a systematic search on PubMed for recently published articles in journals that regularly publish psoriasis studies. After article reduction procedures, randomization, and screening, we reached our target sample of 400 articles. The following non–person-centered language terms were extracted from each article: “Psoriasis Patient,” “Psoriasis subject,” “Affected with,” “Sufferer,” “Suffering from,” “Burdened with,” “Afflicted with,” and “Problems with.” Screening and data extraction occurred in a masked duplicate fashion. Results: Of the 400 included articles, 272 (68%) were not adherent to person-centered language guidelines according to the American Medical Association Manual of Style. The most frequent non–person-centered language term was “Psoriasis Patient,” found in 174 (43.5%) articles. The stigmatizing language was associated with the type of article and funding status, with original investigations and funded studies having higher rates of stigmatizing language. Conclusions: Articles about psoriasis commonly use non–person-centered language terms. It is important to shift away from using stigmatizing language about patients with psoriasis to avoid potential untoward influences. We recommend using “patients with psoriasis” or “patient living with psoriasis” to emphasize the importance of person-centered care.
- 19 March 2021
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 107 (Volume 107) , E23-E25
Asymptomatic Discolored Lesions on the Groin
A 45-year-old African American woman presented with an asymptomatic rash that had worsened over the month prior to presentation. It initially began on the upper thighs and then spread to the abdomen, groin, and buttocks.
- 19 March 2021
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 107 (Volume 107) , E23-E25
Asymptomatic Discolored Lesions on the Groin
A 45-year-old African American woman presented with an asymptomatic rash that had worsened over the month prior to presentation. It initially began on the upper thighs and then spread to the abdomen, groin, and buttocks.